CSNK2A1 and neoplasm: This shows a potential tumor selective vulnerability that can be exploited in PDAC or a subset of PDAC patients since CSNK2A1/3 and CSNK2B were top features in only one of the tumor cell models, P0422-T1 (Fig. 3B).